Lyra Therapeutics, Inc. (LYRA)

NASDAQ: LYRA · IEX Real-Time Price · USD
0.295
-0.015 (-4.80%)
At close: Jun 14, 2024, 4:00 PM
0.298
+0.003 (0.95%)
After-hours: Jun 14, 2024, 7:02 PM EDT
-4.80%
Market Cap 18.00M
Revenue (ttm) 1.68M
Net Income (ttm) -68.88M
Shares Out 60.96M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,699,597
Open 0.306
Previous Close 0.310
Day's Range 0.286 - 0.306
52-Week Range 0.287 - 6.790
Beta 0.02
Analysts Buy
Price Target 4.50 (+1,424.39%)
Earnings Date Aug 6, 2024

About LYRA

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 1, 2020
Employees 109
Stock Exchange NASDAQ
Ticker Symbol LYRA
Full Company Profile

Financial Performance

In 2023, LYRA's revenue was $1.56 million, an increase of 14.31% compared to the previous year's $1.36 million. Losses were -$62.68 million, 13.4% more than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for LYRA stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 1,424.39% from the latest price.

Price Target
$4.5
(1,424.39% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a...

24 days ago - GlobeNewsWire

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“...

5 weeks ago - GlobeNewsWire

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

-- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May -- -- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in...

6 weeks ago - GlobeNewsWire

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal impl...

7 weeks ago - GlobeNewsWire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: L...

3 months ago - GlobeNewsWire

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory ...

3 months ago - GlobeNewsWire

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhino...

7 months ago - GlobeNewsWire

Lyra Therapeutics to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chroni...

7 months ago - GlobeNewsWire

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the loc...

8 months ago - GlobeNewsWire

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Study demonstrates statistically significant and clinically relevant improvements in 3 Cardinal Symptoms and SNOT-22 scores at 24 weeks

9 months ago - GlobeNewsWire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory th...

10 months ago - GlobeNewsWire

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in the Coming Weeks, with Data Expected in 1H 2024 -- -- Initial Topline Re...

11 months ago - GlobeNewsWire

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patien...

1 year ago - GlobeNewsWire

Lyra Therapeutics to Present at Jefferies Healthcare Conference

WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patien...

1 year ago - GlobeNewsWire

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the loc...

1 year ago - GlobeNewsWire

Lyra Therapeutics Announces $50.0 Million Private Placement

WATERTOWN, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the loca...

1 year ago - GlobeNewsWire

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with Data Expected in 1H 2024 -- -- Data from BEACON Phase 2 Trial of LYR-...

1 year ago - GlobeNewsWire

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patient...

1 year ago - GlobeNewsWire

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the lo...

1 year ago - GlobeNewsWire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgica...

1 year ago - GlobeNewsWire

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localiz...

1 year ago - GlobeNewsWire

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra's Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS patients --

1 year ago - GlobeNewsWire

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

-- Company Prioritizing ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS); Study Remains on Track, with Full Enrollment Anticipated mid-2023 -- -- Company to Manufacture All...

1 year ago - GlobeNewsWire

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

21-point (37%) mean improvement in SNOT-22 total score at six weeks during the uncontrolled Part 1 stage of the 24-week BEACON trial First patient dosed in the randomized, Part 2 stage of the BEACON t...

1 year ago - PRNewsWire

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Significantly more patients with moderate/severe symptoms of chronic rhinosinusitis at baseline improved to mild/no symptoms at week 24 after treatment with LYR-210 (7500μg) compared to control The th...

1 year ago - PRNewsWire